Selection of a Patient Subgroup with Advanced Esophageal Squamous Carcinoma Who Could Benefit from Second-Line Chemotherapy

Publisher： Karger

E-ISSN： 1423-0232|79|5-6|363-369

ISSN： 0030-2414

Source： Oncology, Vol.79, Iss.5-6, 2011-03, pp. : 363-369

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Second-Line Antiandrogen Therapy in Japanese Men with Advanced Prostate Cancer Relapsed after Primary Combined Androgen Blockade: Who Will Benefit from Second-Line Hormonal Therapy?

By  

Urologia Internationalis, Vol. 85, Iss. 4, 2010-08 ,pp. : 491-497

Karger

Access to resources Recommend Favorite

S-1 Monotherapy as Second- or Third-Line Chemotherapy for Unresectable and Recurrent Esophageal Squamous Cell Carcinoma

By  

Oncology, Vol. 84, Iss. 5, 2013-04 ,pp. : 305-310

Karger

Access to resources Recommend Favorite

Paclitaxel plus Doxorubicin Chemotherapy as Second-Line Therapy in Patients with Advanced Urothelial Carcinoma Pretreated with Platinum plus Gemcitabine Chemotherapy

By  

Oncology Research and Treatment, Vol. 35, Iss. 10, 2012-09 ,pp. : 576-580

Karger

Access to resources Recommend Favorite

Clinical Outcome of Paclitaxel and Carboplatin as Second-Line Chemotherapy for Advanced Urothelial Carcinoma Resistant to First-Line Therapy with Gemcitabine and Cisplatin

By  

Urologia Internationalis, Vol. 92, Iss. 2, 2013-11 ,pp. : 180-185

Karger

Access to resources Recommend Favorite

Second-Line Chemotherapy in Advanced Bladder Cancer

By  

Urologia Internationalis, Vol. 64, Iss. 2, 2000-05 ,pp. : 61-69

Karger

Access to resources Recommend Favorite